These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8893121)

  • 21. New β-lactam-β-lactamase inhibitor combinations in clinical development.
    Shlaes DM
    Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of the growth of six potentially-pathogenic mycobacteria by beta-lactam/beta-lactamase-inhibitors.
    Prabhakaran K; Harris EB; Randhawa B
    Microbios; 1997; 91(366):7-14. PubMed ID: 9467917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
    Harris PN; Tambyah PA; Paterson DL
    Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic properties of beta-lactamase inhibitors.
    de la Pena A; Derendorf H
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parenteral beta-lactamase inhibitor combinations for clinical use.
    Manzella JP
    Am Fam Physician; 1995 May; 51(7):1695-8. PubMed ID: 7754928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials.
    Lu LC; Lai CC; Chang SP; Lan SH; Hung SH; Lin WT
    Medicine (Baltimore); 2020 May; 99(19):e19960. PubMed ID: 32384444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
    Gin A; Dilay L; Karlowsky JA; Walkty A; Rubinstein E; Zhanel GG
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):365-83. PubMed ID: 17547502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.
    Bush LM; Johnson CC
    Infect Dis Clin North Am; 2000 Jun; 14(2):409-33, ix. PubMed ID: 10829263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
    Rodríguez-Baño J; Navarro MD; Retamar P; Picón E; Pascual Á;
    Clin Infect Dis; 2012 Jan; 54(2):167-74. PubMed ID: 22057701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trials of extended spectrum penicillin/beta-lactamase inhibitors in the treatment of intra-abdominal infections. European and North American experience.
    Wilson SE; Nord CE
    Am J Surg; 1995 May; 169(5A Suppl):21S-26S. PubMed ID: 7755164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors.
    Maddux MS
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):40S-50S. PubMed ID: 2041831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Beta-lactamase inhibitors].
    Launay O; Joly-Guillou ML; Decré D; Crémieux AC
    Presse Med; 1997 Mar; 26(10):485-92. PubMed ID: 9137377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic use in the emergency department. III. The quinolones, new beta lactams, beta lactam combination agents, and miscellaneous antibiotics.
    Schmidt J; Pollack CV
    J Emerg Med; 1996; 14(4):483-96. PubMed ID: 8842923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
    Lode H
    Int J Clin Pract Suppl; 2002 Mar; (125):10-17; discussion 37-9. PubMed ID: 12014852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
    Maseda E; Aguilar L; Gimenez MJ; Gilsanz F
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-lactam resistance: clinical implications for pediatric patients.
    Dajani AS
    J Int Med Res; 2002; 30 Suppl 1():2A-9A. PubMed ID: 11921492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.